

### **In the Claims**

1. (Currently amended) A sustained-release composition comprising a biologically active ~~substance~~ **peptide**, hydroxynaphthoic acid or salt thereof, and a biodegradable polymer or salt thereof.
2. (Cancelled)
3. (Currently amended) A sustained-release composition according to claim ~~2~~ **1** wherein the biologically active peptide is an LH-RH derivative.
4. (Previously presented) A sustained-release composition according to claim 1 wherein the hydroxynaphthoic acid is 3-hydroxy-2-naphthoic acid.
5. (Previously presented) A sustained-release composition according to claim 1 wherein the biodegradable polymer is an  $\alpha$ -hydroxycarboxylic acid polymer.
6. (Previously presented) A sustained-release composition according to claim 5 wherein the  $\alpha$ -hydroxycarboxylic acid polymer is a lactic acid-glycolic acid polymer.
7. (Previously presented) A sustained-release composition according to claim 6 wherein the content ratio of lactic acid and glycolic acid is 100/0 to 40/60 mol%.
8. (Previously presented) A sustained-release composition according to claim 7 wherein

the content ratio of lactic acid and glycolic acid is 100/0 mol%.

9. (Previously presented) A sustained-release composition according to claim 6 wherein the weight-average molecular weight of the polymer is about 3,000 to about 100,000.

10. (Previously presented) A sustained-release composition according to claim 9 wherein the weight-average molecular weight of the polymer is about 20,000 to about 50,000.

11. (Previously presented) A sustained-release composition according to claim 3, wherein the LH-RH derivative is SEQ ID NO.:1.

12. (Previously presented) A sustained-release composition according to claim 6, wherein the terminal carboxyl group content of the polymer is 50-90 micromol of the polymer.

13. (Previously presented) A sustained-release composition according to claim 3, wherein the molar ratio of the hydroxynaphthoic acid or salt thereof and the LH-RH derivative or salt thereof is from 3 to 4 to 4 to 3.

14. (Previously presented) A sustained-release composition according to claim 13, wherein the LH-RH derivative or salt thereof is contained at 14% (w/w) to 24% (w/w).

15. (Currently amended) A sustained-release composition according to claim 1, wherein the ~~bioactive substance~~ biologically active peptide is very slightly soluble in water or soluble in water.

16. (Previously presented) A sustained-release composition according to claim 1, which is intended for injection.

Claims 17-21 (cancelled)

22. (Previously presented) A method of treating prostatic cancer, prostatic hypertrophy, endometriosis, hysteromyoma, metrofibroma, precocious puberty, dysmenorrhea, or breast cancer comprising administering a pharmaceutically effective amount of the sustained-release composition according to claim 11 to a mammal in need thereof.

23. (Previously presented) A sustained-release composition comprising the hydroxynaphthoic acid salt of a bioactive substance and a biodegradable polymer or salt thereof.

Claims 24-28 (cancelled)

29. (Previously presented) A method of contraception comprising administering a pharmaceutically effective amount of the sustained-release composition according to claim 11 to a mammal in need thereof.